Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Nu Holdings
NU
5
Liberty Latin America-A
LILA
CN Stock MarketDetailed Quotes
002370 Zhejiang Yatai Pharmaceutical
- 3.33
- +0.05+1.52%
Not Open Apr 24 15:00 CST
2.48BMarket Cap72.39P/E (TTM)
3.36High3.26Low239.34KlotVolume3.27Open3.28Pre Close79.49MTurnover3.21%Turnover Ratio72.39P/E (Static)745.67MShares4.3852wk High2.61P/B2.48BFloat Cap2.2152wk Low3.61Limit Up745.67MShs Float22.10Historical High2.95Limit Down3.05%Amplitude2.21Historical Low--Dividend TTM3.32Avg Price113.70KlotAsk--Div YieldTTM100Lot Size125.59KlotBid
Zhejiang Yatai Pharmaceutical News
Asia Pacific Pharmaceuticals: 2024 Annual Report Summary
Asia Pacific Pharmaceuticals: Annual Report 2024
Zhejiang Yatai Pharmaceutical (002370.SZ): received a government subsidy of 3 million yuan.
Gelonghui April 18丨Zhejiang Yatai Pharmaceutical (002370.SZ) announced that the company recently received a government subsidy of 3 million yuan, accounting for 25.26% of the absolute value of the Net income attributable to the listed company's Shareholders in the most recent audited period.
Shareholders in Zhejiang Yatai Pharmaceutical (SZSE:002370) Have Lost 53%, as Stock Drops 16% This Past Week
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Zhejiang Yatai Pharmaceutical (002370.SZ): intends to transfer 100% equity of Xingya Pharmaceutical to Zhejiang Zhongqingda.
On March 31, Gelonghui reported that Zhejiang Yatai Pharmaceutical (002370.SZ) announced that on March 31, 2025, the company signed the "Equity Transfer Agreement regarding Shaoxing Xingya Pharmaceutical Co., Ltd." with Zhejiang Zhongqingda Construction Industry Co., Ltd. (hereinafter referred to as "Zhejiang Zhongqingda" or "the transferee"), transferring 100% of the shares of Shaoxing Xingya Pharmaceutical Co., Ltd. (hereinafter referred to as "Xingya Pharmaceutical" or "the symbol company") held by the company to Zhejiang Zhongqingda. As of the date of signing the Equity Transfer Agreement, Xingya Pharmaceutical owes the company a loan of RMB 48.7289 million. Through mutual agreement, this Trade adopts a debt assumption.
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Zhejiang Yatai Pharmaceutical (002370.SZ): The injectable form of Ganciclovir has passed the consistency evaluation for generic drugs.
On February 25, Gelonghui reported that Zhejiang Yatai Pharmaceutical (002370.SZ) announced it recently received the approved notification from the National Medical Products Administration regarding the supplementary application for injectable Ganciclovir. The injectable Ganciclovir has passed the consistency evaluation of generic drug quality and efficacy. Injectable Ganciclovir is suitable for the treatment of life-threatening or sight-threatening cytomegalovirus infections in immunocompromised patients, as well as for the prevention of cytomegalovirus infections in organ transplant patients.
Zhejiang Yatai Pharmaceutical (002370.SZ): Tigecycline for injection has obtained the Pharmaceutical registration certificate.
On February 7, Gelonghui reported that Zhejiang Yatai Pharmaceutical (002370.SZ) announced that the company recently received the Drug Registration Certificate for Injectable Tigecycline approved and issued by the National Medical Products Administration. Injectable Tigecycline is suitable for patients aged 18 and older for infections caused by specific strains of sensitive bacteria, including: complicated intra-abdominal infections due to sensitive strains of Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Enterococcus faecalis (limited to vancomycin-sensitive strains), and Staphylococcus aureus (methicillin-sensitive strains and methicillin-resistant strains.
Yatai Pharmaceutical Gets Nod to Make Amendments to Diltiazem Hydrochloride for Injection
Asia Pacific Pharmaceutical: 2024 Annual Results Forecast
Zhejiang Yatai Pharmaceutical (002370.SZ): Currently, there are no innovative drugs related to influenza.
On January 8, Gelonghui reported that Zhejiang Yatai Pharmaceutical (002370.SZ) stated on the investor interaction platform that the company currently does not have any Innovative Drugs related to influenza, and its main products are antibiotics, gastrointestinal medications, antiviral drugs, cardiovascular drugs, and antipyretic and analgesic pharmaceuticals.
Zhejiang Yatai Pharmaceutical (SZSE:002370 Shareholders Incur Further Losses as Stock Declines 15% This Week, Taking Five-year Losses to 47%
Zhejiang Yatai Pharmaceutical (002370.SZ): Received the approval notification for the supplementary application of injectable Cefoperazone Sodium Pharmaceutical.
On December 13, Gelonghui reported that Zhejiang Yatai Pharmaceutical (002370.SZ) announced that the company recently received the "Notification of Approval for Supplemental Application of Pharmaceuticals" issued by the National Medical Products Administration for injectable cefmetazole sodium. Cefmetazole sodium is highly stable against β-lactamase and has strong antibacterial activity against both β-lactamase-producing and non-producing sensitive bacteria. It has good antibacterial effects against Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis, and is also effective against common Proteus species that are resistant to cephalosporins and penicillin antibiotics.
Zhejiang Yatai Pharmaceutical (002370.SZ): Termination of the funding project for Convertible Bonds.
On December 11, Ge Long Hui reported that Zhejiang Yatai Pharmaceutical (002370.SZ) announced that at the 33rd meeting of the 7th Board of Directors and the 18th meeting of the 7th Supervisory Board held on December 11, 2024, it approved the "Proposal for Terminating the Fundraising Project for Convertible Bonds." 1. The Phase I and II projects of Zhejiang Yatai Pharmaceutical Modern Pharmaceutical Formulations consist of two independent lyophilized powder injection workshops, a penicillin workshop, a solid preparations workshop, a cephalosporin workshop (capsules and powder injections), a patch workshop, a raw and auxiliary materials finished product warehouse, a quality inspection workshop, a Sewerage treatment center, and dormitories.
Zhejiang Yatai Pharmaceutical (002370.SZ): Injectable Pantoprazole Sodium passed the consistency evaluation.
Zhejiang Yatai Pharmaceutical (002370.SZ) announced that the company recently received approval and issuance of the State Food and Drug Administration regarding...
Zhejiang Yatai Pharmaceutical's Diltiazem Hydrochloride Tablets Enter Consistency Evaluation Review Stage
Asia Pacific Pharmaceutical: Report for the third quarter of 2024
zhejiang yatai pharmaceutical (002370.SZ): a net loss of 3.4595 million yuan in the first three quarters.
Gelonghui On October 30th, Zhejiang Yatai Pharmaceutical (002370.SZ) released its third-quarter report for 2024, achieving revenue of 0.307 billion yuan in the first three quarters, a year-on-year increase of 1.65%; net income attributable to the shareholders of the listed company was -3.4595 million yuan; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was -22.5921 million yuan; basic earnings per share was -0.0056 yuan.
Zhejiang Yatai Pharmaceutical (002370.SZ): Plans to sell 100% equity and debt forgiveness of Shanghai Xingaofeng.
On September 9th, GeLonghui reported that Zhejiang Yatai Pharmaceutical (002370.SZ) announced that at the 31st meeting of the seventh board of directors held on September 9th, 2024, it passed the "Proposal on the sale of 100% equity and debt exemption of wholly-owned subsidiary". On September 9th, 2024, the company signed the "Equity Transfer Agreement of Shanghai Xingaofeng Biomedical Co., Ltd." with Ningbo Heyi Culture Media Co., Ltd. (referred to as "Heyi Culture"), transferring 100% equity of Shanghai Xingaofeng Biomedical Co., Ltd. (referred to as "Shanghai Xingaofeng") held by the company to Heyi Culture. Due to Shanghai.
Market Insights
Warren Buffett Portfolio Warren Buffett Portfolio
Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.
Unlock Now
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 9 20:29
Learning From Buffett: Investing Wisely Amid Market Volatility Triggered by Trump's Tariffs